In a de novo study, high frequency of FLT3-ITD mutations at relapse was associated with TET2 or IDH1/2 mutations suggesting that mutations in epigenetic regulators in AML may induce FLT3-ITD mutations through genetic instability and it may lead to relapse and resistance to therapy [196]. The gene discussed is IDH1; the disease is acute myeloid leukemia.